Compliance with treatment of osteoporosis with bisphosphonate;Komplians ved behandling af osteoporose med bisfosfonat

Ugeskrift for Laeger

Volumn 166, Issue 1-2, 2004, Pages 49-53

  Wulff, Rasmus ^a,b   Abrahamsen, Bo ^a   Ejersted, Charlotte Albjerg ^a   Christensen, Palle Mark ^a   Brixen, Kim T ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ETIDRONIC ACID;

ACADEMIC ACHIEVEMENT; ARTICLE; BONE MINERAL; CLINICAL PRACTICE; CORRELATION ANALYSIS; DRUG COST; EDUCATION; FEMALE; FRACTURE; GENERAL PRACTICE; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT REFERRAL; POSTMENOPAUSE OSTEOPOROSIS; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT;

EID: 0742288998     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Mosekilde L, Beck-Nielsen H, Sørensen OH et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas 2000;36: 181-93.
2. Komulainen MH, Kroger H, Tupparainen MT et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal woman; a 5 year randomized trial. Maturitas 1998;31:45-54.
3. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Annals Inter Med 1992;117:1-9.
4. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
5. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
6. Lieberman UA, Weiss SR, Brõll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
7. Storm T, Thamsborg G, Steiniche T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
8. Watts NB, Harris ST, Gennant HK et al. III Intermittent cyclical etidronate treatment of postmenopusal osteoporosis. N Engl J Med 1990;323:73-9.
9. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in woman with established postmenopausal osteoporosis. Vertebral efficacy with Risedronate therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
10. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
11. Chapuy MC, Arlot ME, Delmas PD et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly woman. BMJ 1994;308: 1081-2.
12. Dawson-Hughes B, Harris SS et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
13. Bloom BS. Daily regimen and compliance with treatment. BMJ 2001;323: 647.
14. Salamone LM, Pressman AR, Seeley DG et al. Estrogen replacement therapy - a survey of older women's attitudes. Arch Intern Med 1996;156:1293-7.
15. Mersfelder T, Armitstead JA, Ivey MF et al. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manage Q 1999;18:50-8.
16. McClung MR, Geusens P, Miller P et al. Effects of risedronate on the risk of hip fracture in elderly womem. N Engl J Med 2001;344:333-40.
17. Faulkner DL, Young C, Hutchins D et al. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-9.
18. Ryan PJ, Harrison R, Blake GM et al. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-8.
19. Vestergaard P, Hermann AP, Gram J et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997; 28:137-45.
20. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996;19: 191-3.
21. Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507-12.
22. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736-46.
23. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12:1-12.
24. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.